Immuron to participate in h.c. wainwright & co. bioconnect 2021 virtual conference

Melbourne, australia, jan. 11, 2021 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to announce that chief executive officer, dr jerry kanellos, will participate in the h.c. wainwright & co. bioconnect 2021 virtual conference in january 2021 during j.p. morgan week.
IMRN Ratings Summary
IMRN Quant Ranking